

Hospitalist's Corner: SGLT2 Inhibitors in the Treatment of Heart Failure

presented by

Anthony Benaquista, MD

Thursday, November 4, 2021

Hospital of Central Connecticut, Cafeteria

Learning Objectives: *As a result of participating in this Live Activity, participants should be able to:*

- 1 Describe the mechanism of action of SGLT-2 inhibitors*
- 2 Discuss results of EMPA-REG, DAPA-HF, and EMPORER trials assessing SGLT2 inhibitors in HFrEF*
- 3 Discuss evidence for benefits of SGLT-2 inhibitors in preserved EF and non-diabetics*

Accreditation Statement: In support of improving patient care, Hartford HealthCare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation Statement: Hartford Healthcare designates this Live Activity for 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with their participation.

Financial Disclosures:

Name of individual	Individual's role in activity	Name of commercial interest/Nature of relationship
James Barrett, Administrator	Activity Coordinator	Nothing to disclose - 06/04/2021
Thomas Lane, MD, FACP	Course Director	Nothing to disclose - 12/22/2020
Anthony Benaquista, MD	Faculty	Nothing to disclose - 10/29/2021



